Background: Randomized comparisons have demonstrated survival benefit of adjuvant immunotherapy in node-positivemelanoma patients but have limited power to determine if this benefit persists across various demographic factors.
Materials & methods: We assessed the impact of demographic factors on the survival benefit of adjuvant immunotherapy in a database of 38,189 node-positive melanoma patients using the Kaplan–Meier method and Cox proportional hazards models.
Results: All assessed demographic factors other than race significantly impacted survival of node-positive melanoma patients in univariate analysis. In multivariable analysis, only the age group interacted with immunotherapy.
Conclusion: Analysis of this large database of unselected node-positive melanoma patients demonstrated a positive survival benefit of immunotherapy across all demographic factors assessed and the impact was greater for patients 65 years of age and older.
Ikeguchi, A., Machiorlatti, M., & Vesely, S. K. (2020). Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. Melanoma management, 7(2), MMT43. https://doi.org/10.2217/mmt-2020-0002
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Population Health and Biostatistics